Does the media prefer AUPH or PCVX?

In the previous week, Vaxcyte had 1 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 5 mentions for Vaxcyte and 4 mentions for Aurinia Pharmaceuticals. Vaxcyte's average media sentiment score of 0.89 beat Aurinia Pharmaceuticals' score of -0.07 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vaxcyte 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IBRX or AUPH?

In the previous week, ImmunityBio had 1 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 5 mentions for ImmunityBio and 4 mentions for Aurinia Pharmaceuticals. ImmunityBio's average media sentiment score of 1.14 beat Aurinia Pharmaceuticals' score of -0.07 indicating that ImmunityBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 5 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aurinia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor RYTM or AUPH?

In the previous week, Rhythm Pharmaceuticals had 2 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 6 mentions for Rhythm Pharmaceuticals and 4 mentions for Aurinia Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.40 beat Aurinia Pharmaceuticals' score of -0.07 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aurinia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AUPH or MIRM?

In the previous week, Aurinia Pharmaceuticals and Aurinia Pharmaceuticals both had 4 articles in the media. Mirum Pharmaceuticals' average media sentiment score of 0.24 beat Aurinia Pharmaceuticals' score of -0.07 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Mirum Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AUPH or LNTH?

In the previous week, Aurinia Pharmaceuticals and Aurinia Pharmaceuticals both had 4 articles in the media. Lantheus' average media sentiment score of 0.98 beat Aurinia Pharmaceuticals' score of -0.07 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurinia Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lantheus 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Aurinia Pharmaceuticals (AUPH) Competitors

$15.42 +0.18 (+1.15%)

As of 11:50 AM Eastern

Compare

AUPH vs. PCVX, IBRX, RYTM, MIRM, and LNTH

Should you buy Aurinia Pharmaceuticals stock or one of its competitors? MarketBeat compares Aurinia Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aurinia Pharmaceuticals include Vaxcyte (PCVX), ImmunityBio (IBRX), Rhythm Pharmaceuticals (RYTM), Mirum Pharmaceuticals (MIRM), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry.

How does Aurinia Pharmaceuticals compare to Vaxcyte?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

Aurinia Pharmaceuticals has a net margin of 99.97% compared to Vaxcyte's net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.62% beat Vaxcyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%
Vaxcyte	N/A	-32.51%	-29.51%

Aurinia Pharmaceuticals presently has a consensus price target of $17.25, suggesting a potential upside of 11.90%. Vaxcyte has a consensus price target of $86.00, suggesting a potential upside of 56.21%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts plainly believe Vaxcyte is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29
Vaxcyte	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44

Aurinia Pharmaceuticals has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market.

Aurinia Pharmaceuticals has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$298.30M	6.65	$287.20M	$2.17	7.10
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

In the previous week, Vaxcyte had 1 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 5 mentions for Vaxcyte and 4 mentions for Aurinia Pharmaceuticals. Vaxcyte's average media sentiment score of 0.89 beat Aurinia Pharmaceuticals' score of -0.07 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vaxcyte	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.8% of Vaxcyte shares are owned by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are owned by insiders. Comparatively, 3.3% of Vaxcyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Aurinia Pharmaceuticals beats Vaxcyte on 9 of the 15 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, media sentiment, risk, dividends, analyst recommendations, profitability and earnings.

Aurinia Pharmaceuticals has a net margin of 99.97% compared to ImmunityBio's net margin of -606.15%. Aurinia Pharmaceuticals' return on equity of 26.62% beat ImmunityBio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%

ImmunityBio has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market. Comparatively, Aurinia Pharmaceuticals has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market.

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 66.1% of ImmunityBio shares are held by company insiders. Comparatively, 10.4% of Aurinia Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, ImmunityBio had 1 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 5 mentions for ImmunityBio and 4 mentions for Aurinia Pharmaceuticals. ImmunityBio's average media sentiment score of 1.14 beat Aurinia Pharmaceuticals' score of -0.07 indicating that ImmunityBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	5 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aurinia Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aurinia Pharmaceuticals has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	67.26	-$351.40M	-$0.85	N/A
Aurinia Pharmaceuticals	$298.30M	6.65	$287.20M	$2.17	7.10

ImmunityBio presently has a consensus target price of $14.20, suggesting a potential upside of 95.19%. Aurinia Pharmaceuticals has a consensus target price of $17.25, suggesting a potential upside of 11.90%. Given ImmunityBio's stronger consensus rating and higher possible upside, research analysts plainly believe ImmunityBio is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Aurinia Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29

Summary

Aurinia Pharmaceuticals beats ImmunityBio on 9 of the 16 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

Rhythm Pharmaceuticals has a beta of 1.88, suggesting that its stock price is 88% more volatile than the broader market. Comparatively, Aurinia Pharmaceuticals has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market.

In the previous week, Rhythm Pharmaceuticals had 2 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 6 mentions for Rhythm Pharmaceuticals and 4 mentions for Aurinia Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.40 beat Aurinia Pharmaceuticals' score of -0.07 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aurinia Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rhythm Pharmaceuticals presently has a consensus price target of $138.29, indicating a potential upside of 32.72%. Aurinia Pharmaceuticals has a consensus price target of $17.25, indicating a potential upside of 11.90%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Rhythm Pharmaceuticals is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.76
Aurinia Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29

Aurinia Pharmaceuticals has a net margin of 99.97% compared to Rhythm Pharmaceuticals' net margin of -93.33%. Aurinia Pharmaceuticals' return on equity of 26.62% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by company insiders. Comparatively, 10.4% of Aurinia Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Aurinia Pharmaceuticals has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	37.63	-$196.54M	-$3.13	N/A
Aurinia Pharmaceuticals	$298.30M	6.65	$287.20M	$2.17	7.10

Summary

Aurinia Pharmaceuticals beats Rhythm Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to Mirum Pharmaceuticals?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Aurinia Pharmaceuticals has a net margin of 99.97% compared to Mirum Pharmaceuticals' net margin of -140.24%. Aurinia Pharmaceuticals' return on equity of 26.62% beat Mirum Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Aurinia Pharmaceuticals presently has a consensus price target of $17.25, indicating a potential upside of 11.90%. Mirum Pharmaceuticals has a consensus price target of $143.40, indicating a potential upside of 26.68%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

In the previous week, Aurinia Pharmaceuticals and Aurinia Pharmaceuticals both had 4 articles in the media. Mirum Pharmaceuticals' average media sentiment score of 0.24 beat Aurinia Pharmaceuticals' score of -0.07 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mirum Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aurinia Pharmaceuticals has higher earnings, but lower revenue than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$298.30M	6.65	$287.20M	$2.17	7.10
Mirum Pharmaceuticals	$521.31M	13.24	-$23.36M	-$13.61	N/A

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are held by insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Aurinia Pharmaceuticals has a beta of 1.41, meaning that its share price is 41% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.48, meaning that its share price is 52% less volatile than the broader market.

Summary

Aurinia Pharmaceuticals beats Mirum Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Aurinia Pharmaceuticals compare to Lantheus?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

Aurinia Pharmaceuticals has higher earnings, but lower revenue than Lantheus. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$298.30M	6.65	$287.20M	$2.17	7.10
Lantheus	$1.55B	4.41	$233.56M	$4.15	25.24

Aurinia Pharmaceuticals presently has a consensus target price of $17.25, suggesting a potential upside of 11.90%. Lantheus has a consensus target price of $110.43, suggesting a potential upside of 5.43%. Given Aurinia Pharmaceuticals' higher probable upside, equities analysts clearly believe Aurinia Pharmaceuticals is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.29
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Aurinia Pharmaceuticals has a net margin of 99.97% compared to Lantheus' net margin of 18.05%. Lantheus' return on equity of 29.32% beat Aurinia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%
Lantheus	18.05%	29.32%	15.00%

In the previous week, Aurinia Pharmaceuticals and Aurinia Pharmaceuticals both had 4 articles in the media. Lantheus' average media sentiment score of 0.98 beat Aurinia Pharmaceuticals' score of -0.07 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aurinia Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lantheus	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aurinia Pharmaceuticals has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market.

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are held by company insiders. Comparatively, 1.7% of Lantheus shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Lantheus beats Aurinia Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Aurinia Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AUPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AUPH vs. The Competition

Export

Metric	Aurinia Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.98B	$3.06B	$6.88B	$12.20B
Dividend Yield	N/A	2.06%	2.68%	9.43%
P/E Ratio	7.08	20.29	26.92	23.72
Price / Sales	6.65	337.69	517.00	90.63
Price / Cash	15.13	27.50	50.43	59.93
Price / Book	3.50	4.14	10.02	6.10
Net Income	$287.20M	$65.94M	$3.60B	$331.84M
7 Day Performance	-3.41%	-3.97%	-0.92%	-1.05%
1 Month Performance	-17.21%	-4.46%	-0.25%	-2.60%
1 Year Performance	69.97%	9.62%	19.04%	13.86%

Aurinia Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AUPH Aurinia Pharmaceuticals	3.095 of 5 stars	$15.42 +1.2%	$17.25 +11.9%	+65.8%	$1.98B	$298.30M	7.08	300	News Coverage Upcoming Earnings Analyst Downgrade
PCVX Vaxcyte	2.4518 of 5 stars	$55.50 -1.2%	$86.00 +55.0%	+52.6%	$8.12B	N/A	N/A	160
IBRX ImmunityBio	3.3474 of 5 stars	$7.49 -2.5%	$14.20 +89.6%	+147.5%	$8.04B	$113.29M	N/A	590	Positive News
RYTM Rhythm Pharmaceuticals	2.8891 of 5 stars	$104.60 -1.9%	$138.29 +32.2%	+16.9%	$7.31B	$189.76M	N/A	140	Gap Down
MIRM Mirum Pharmaceuticals	2.7738 of 5 stars	$116.62 -1.9%	$143.40 +23.0%	+115.6%	$7.25B	$521.31M	N/A	140	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AUPH) was last updated on 7/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aurinia Pharmaceuticals (AUPH) Competitors

AUPH vs. PCVX, IBRX, RYTM, MIRM, and LNTH

How does Aurinia Pharmaceuticals compare to Vaxcyte?

Summary

How does Aurinia Pharmaceuticals compare to ImmunityBio?

Summary

How does Aurinia Pharmaceuticals compare to Rhythm Pharmaceuticals?

Summary

How does Aurinia Pharmaceuticals compare to Mirum Pharmaceuticals?

Summary

How does Aurinia Pharmaceuticals compare to Lantheus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUPH vs. The Competition

Aurinia Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aurinia Pharmaceuticals (AUPH) Competitors

AUPH vs. PCVX, IBRX, RYTM, MIRM, and LNTH

How does Aurinia Pharmaceuticals compare to Vaxcyte?

Is AUPH or PCVX more profitable?

Do analysts prefer AUPH or PCVX?

Which has more volatility and risk, AUPH or PCVX?

Which has better valuation and earnings, AUPH or PCVX?

Does the media prefer AUPH or PCVX?

Do institutionals & insiders hold more shares of AUPH or PCVX?

Summary

How does Aurinia Pharmaceuticals compare to ImmunityBio?

Is IBRX or AUPH more profitable?

Which has more volatility & risk, IBRX or AUPH?

Do institutionals and insiders hold more shares of IBRX or AUPH?

Does the media refer more to IBRX or AUPH?

Which has better earnings & valuation, IBRX or AUPH?

Do analysts prefer IBRX or AUPH?

Summary

How does Aurinia Pharmaceuticals compare to Rhythm Pharmaceuticals?

Which has more volatility and risk, RYTM or AUPH?

Does the media favor RYTM or AUPH?

Do analysts prefer RYTM or AUPH?

Is RYTM or AUPH more profitable?

Do institutionals & insiders have more ownership in RYTM or AUPH?

Which has stronger earnings & valuation, RYTM or AUPH?

Summary

How does Aurinia Pharmaceuticals compare to Mirum Pharmaceuticals?

Is AUPH or MIRM more profitable?

Do analysts recommend AUPH or MIRM?

Does the media favor AUPH or MIRM?

Which has stronger valuation and earnings, AUPH or MIRM?

Do institutionals and insiders have more ownership in AUPH or MIRM?

Which has more risk and volatility, AUPH or MIRM?

Summary

How does Aurinia Pharmaceuticals compare to Lantheus?

Which has stronger valuation and earnings, AUPH or LNTH?

Do analysts recommend AUPH or LNTH?

Is AUPH or LNTH more profitable?

Does the media refer more to AUPH or LNTH?

Which has more risk & volatility, AUPH or LNTH?

Do institutionals & insiders believe in AUPH or LNTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AUPH vs. The Competition

Aurinia Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools